Pharmacological Modulation of Cisplatin Toxicity Rhythms with Buthionine Sulfoximine in Mice Bearing Pancreatic Adenocarcinoma (PO3)

References

• Meister A. Metabolism and transport of glutathione and other γ-glutamyl compounds. Functions of glutathione: biochemical, physiological, toxicological, and clinical aspects, A Larson, S Orrenius, A Holmgren, B Mannervik. Raven Press, New York 1983; 1–22
   Google Scholar
• Reed D J. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol 1990; 30: 603–31
   PubMed Web of Science ®Google Scholar
• Hamers F PT, Brakkee J H, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt J P, Gispen W H. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53: 544–49
   PubMed Web of Science ®Google Scholar
• Li X M, Metzger G, Filipski E, Boughattas N, Lemaigre G, Hecquet B, Filipski J, Lévi F. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice. Toxicol Appl Pharmacol 1997; 143: 281–90
   PubMed Web of Science ®Google Scholar
• Arrick B A, Nathan C F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984; 44: 4224–32
   PubMed Web of Science ®Google Scholar
• Smith C V, Jones D P, Quenthner T M, Lash L H, Lauterburg H L. Contemporary issues in toxicology, compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol Appl Pharmacol 1996; 140: 1–12
   PubMed Web of Science ®Google Scholar
• Richon V M, Schulte N, Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 1987; 47: 2056–61
   PubMed Web of Science ®Google Scholar
• Meijer C, Mulder N H, Timmer-Bosscha H, Sluiter W J, Meersma G J, De Vries E GE. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 1992; 52: 6885–89
   PubMed Web of Science ®Google Scholar
• Timmer-Bosscha H, Timmer A, Meijer C, de Vries E GE, de Jong B, Oosterhuis W, Mulder N H. Cis-diamminedichloroplatinum(II) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res 1993; 53: 5707–13
   Google Scholar
• Griffith O W, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine. J Biol Chem 1987; 254: 7558–60
   Google Scholar
• Griffith O W. L-Buthionine-SR-sulfoximine: mechanism of action, resolution of dia-stereomers and as a chemotherapeutic agent. Glutathione centennial, N Taniguchi, T Higashi, Y Sakamoto, A Meister. Academic, San Diego, CA 1989; 285–99
   Google Scholar
• Hamilton T C, Winker M A, Louie K G, Batist G, Brhrens B C, Tsuruo T, Grotzinger K R, McKoy W M, Young R C, Ozols R F. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34: 2583–86
   PubMed Web of Science ®Google Scholar
• Andrews P A, Schiefer M A, Murphy M P, Howell S B. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact 1988; 65: 51–58
   PubMed Web of Science ®Google Scholar
• Bier H. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo. Acta Oto-laryngol 1991; 111: 797–806
   PubMed Web of Science ®Google Scholar
• Saikawa Y, Kubota T, Kuo T H, Furukawa T, Tanino H, Watanabe M, Ishibiki K, Kitajima M. Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine. Jpn J Cancer Res 1993; 84: 787–93
   PubMedGoogle Scholar
• Bailey H, Mulcahy R T, Tutsch K D, Arzoomanian R Z, Alberti D, Feierabend C, Tombes M B, Wilding G, Spriggs D. Phase I trail of intravenous melphalan (L-PAM) and L-buthionine sulfoximine (BSO): an attempt at modulation of glutathione (GSH) chemoprotection [abstr]. Proc Am Soc Clin Oncol 1992; 11: 114
   Google Scholar
• O'Dwyer P J, Hamilton T C, Lacreta F P, Gallo J M, Kilpatrick D, Halbherr T, Brennan J, Bookman M A, Hoffman J, Young R C, Comis R L, Ozols R F. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14: 249–56
   PubMed Web of Science ®Google Scholar
• Hrushesky W, Lévi F, Halberg F, Kennedy B J. Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res 1982; 42: 945–49
   PubMed Web of Science ®Google Scholar
• Lévi F, Hrushesky W, Blomquist J, Lakatua D, Haus E, Halberg F, Kennedy B J. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res 1982; 42: 950–55
   PubMed Web of Science ®Google Scholar
• Boughattas N A, Lévi F, Hecquet B, Lemaigre G, Roulon A, Fournier C, Reinberg A. Circadian time dependence of murine tolerance for carboplatin. Toxicol Appl Pharmacol 1988; 96: 233–47
   PubMed Web of Science ®Google Scholar
• Boughattas N A, Lévi F, Fournier C, Lemaigre G, Roulon A, Hecquet B, Mathé G, Reinberg A. Circadian rhythm in toxicities and tissue uptake of 1,2-diaminocyclohexane (trans-1) oxalatoplatinum (II) in mice. Cancer Res 1989; 49: 3362–68
   PubMed Web of Science ®Google Scholar
• Boughattas N A, Lévi F, Fournier C, Hecquet B, Lemaigre G, Roulon A, Mathé G, Reinberg A. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J Pharmacol Exp Therap 1990; 255: 672–79
   PubMed Web of Science ®Google Scholar
• Sothern R, Lévi F, Haus E, Halberg F, Hrushesky W JM. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Nat Cancer Inst 1989; 81: 135–45
   PubMedGoogle Scholar
• Bissery M C, Guénard D, Guéritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, /NSC 628503), a taxol analogue. Cancer Res 1991; 51: 4845–52
   PubMed Web of Science ®Google Scholar
• Ellman G L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70–77
   PubMed Web of Science ®Google Scholar
• Nelson W, Tong Y, Lee J K, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979; 6: 305–23
   PubMedGoogle Scholar
• Kramer R A, Greene K, Ahmad S, Vistica D T. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res 1987; 47: 1593–97
   PubMed Web of Science ®Google Scholar
• Prezioso J A, FitzGerald G B, Wick M M. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J Invest Dermatol 1992; 99: 289–93
   PubMed Web of Science ®Google Scholar
• Port J L, Hochwald S N, Wang H Y, Burt M E. Buthionine sulfoximine pretreatment potentiates the effect of isolated lung perfusion with doxorubicin. Ann Thorac Surg 1995; 60: 239–44
   PubMed Web of Science ®Google Scholar
• Corbett T H, Roberts B J, Leopold W R, Peckham J C, Wilkoff L J, Griswold D P, Jr, Schabel F M, Jr. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984; 44: 717–26
   PubMed Web of Science ®Google Scholar
• Hrushesky W JM. Orcadian timing of cancer chemotherapy. Science 1985; 228: 73–75
   PubMed Web of Science ®Google Scholar
• Lévi F, Benvavides J, Chevelle C, Le Saunier F, Bailleul F, Misset J L, Regensberg C, Vannetzel J M, Reinberg A, Mathé G. Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyI adriamycin (THP) and cisplatin: a phase II trial with an evaluation of circadian timing and dose intensity. J Clin Oncol 1990; 8: 705–14
   PubMed Web of Science ®Google Scholar
• Caussanel J P, Lévi F, Brienza S, Misset J L, Itzhaki M, Adam R, Milano G, Hecquet B, Mathé G. Phase I trial of five-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Nat Cancer Inst 1990; 82: 1046–50
   PubMed Web of Science ®Google Scholar
• Lévi F, Zidani R, Misset J L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–86
   PubMed Web of Science ®Google Scholar
• Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprés-Brummer P, Brienza S, Adam R, Kunstlinger F, Bismuth H, Misset J L, Lévi F. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 2950–58
   PubMed Web of Science ®Google Scholar
• Lévi F. Chronopharmacology of anticancer agents. Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms, P H Redfern, B Lemmer. Springer-Verlag, Berlin 1997; 299–331, 125
   Google Scholar